Full Text
Cost Analysis of Certolizumab Pegol Compared With Available Biologic Agents For Crohn’s Disease In Mexico And Brazil

Abstract

Authors

A Aguirre M Naranjo H Bierschwale M Treglia

Back to Volume 18, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×